Baird Medical Investment Holdings Ltd. reported preliminary unaudited financial results for the six months ended June 30, 2026, showing a 24.6% increase in revenue to approximately $9.9 million from $8.0 million in the same period last year, driven by growth in the United States and other strategic markets. Gross profit rose 32.0% to $8.6 million, with gross margin expanding to 87.0% from 82.1%. The company achieved net income of approximately $14,000, compared to a net loss of $11.4 million in the prior-year period, and reported EBITDA of $1.6 million and adjusted EBITDA of $4.0 million, versus losses of $9.7 million and $3.3 million respectively. Approximately two-thirds of revenue came from outside China, with the U.S. contributing about 27% of revenue, up from less than 2% in the first half of 2025. Chairwoman and CEO Haimei Wu attributed the results to successful execution of the international growth strategy and reduced operating expenses, while U.S. subsidiary CEO Mark Saxton noted the commercial expansion is ahead of plan.
Baird Medical Investment Holdings LimitedReports 24.6% revenue growth, positive net income, and improved EBITDA.
